Summary: CytoReason shifts focus to drug development and Sanofi partnership

Why It Matters: The company is moving its messaging from general "predictable medicine" to specific "drug development." They are also highlighting a long-term extension of their work with a major pharmaceutical partner, Sanofi.

What Changed:

• Updated the main headline from "predictable medicine" to "predictable drug development."
• Added a new featured press release about extending their AI collaboration with Sanofi through 2026.
• Removed several navigation links including Careers, Technology, and Solutions pages.
• Removed the "Scientific Publications" section from the news feed.
• Removed the "Get inside the model" and "See how disease models work" call-to-action buttons.
• Removed the accessibility toolbar and footer legal links.